Publicaciones en colaboración con investigadores/as de University of Calgary (11)

2023

  1. Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads

    Journal of Interventional Cardiac Electrophysiology, Vol. 66, Núm. 7, pp. 1589-1600

2022

  1. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

    ESMO Open, Vol. 7, Núm. 4

2021

  1. An experimental study revisiting the link between media attention and breast cancer concern: exploring the role of cognitive fusion

    Women and Health, Vol. 61, Núm. 10, pp. 976-985

2020

  1. Further delineation of the clinical spectrum of KAT6B disorders and allelic series of pathogenic variants

    Genetics in Medicine, Vol. 22, Núm. 8, pp. 1338-1347

2017

  1. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely Ill medical patients: An APEX trial substudy

    Journal of the American Heart Association, Vol. 6, Núm. 7

  2. The relevance of experiential avoidance in breast cancer distress: insights from a psychological group intervention

    Psycho-Oncology, Vol. 26, Núm. 4, pp. 469-475

2014

  1. Oxytocin and pain: A systematic review and synthesis of findings

    Clinical Journal of Pain, Vol. 30, Núm. 5, pp. 453-462

2013

  1. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

    Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649

2012

  1. Attention-deficit hyperactivity disorder and cardiac vagal control: A systematic review

    ADHD Attention Deficit and Hyperactivity Disorders, Vol. 4, Núm. 4, pp. 167-177

2011

  1. Segundo Consenso Clínico de la Sociedad Iberoamericana de Neonatología: Manejo hemodinámico del recién nacido

    Revista Panamericana de Salud Publica/Pan American Journal of Public Health, Vol. 29, Núm. 4, pp. 281-302

2009

  1. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

    Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228